By Our Reporter
The U.S. government under President Donald Trump has donated 100 vials of monoclonal antibodies. These life-saving treatments are scientifically proven to improve survival chances in patients infected with the Sudan strain of Ebola — the variant responsible for the 2025 outbreak in Uganda.
The donation arrives just as the country approaches the tail end of its latest Ebola outbreak, bringing renewed hope for health workers and patients alike.
According to Uganda’s Ministry of Health, this support is critical in treating severe cases and preventing future flare-ups, especially in high-risk regions.
Monoclonal antibodies work by targeting the Ebola virus in the body and blocking its ability to infect cells, offering an advanced line of defense for those who contract the disease.
Health experts say their use can drastically reduce fatalities, especially when administered early.
This development comes only days after the Trump administration controversially pulled funding from UNAIDS programs in Uganda, citing disagreements over policy and accountability concerns.
The sudden cut caused worry among HIV/AIDS activists and health advocates, who rely heavily on international funding for life-saving programs.
Observers see the Ebola-related donation as a strategic effort by the Trump administration to maintain a presence in Uganda’s health sector while shifting priorities.
Some have described it as a calculated move to reassure the Ugandan government of continued U.S. support in selected areas.
While questions remain over the long-term impact of the UNAIDS funding cut, the Ebola donation is being welcomed as a timely and potentially life-saving gesture.
With the outbreak nearly under control, the added support strengthens Uganda’s emergency response systems and shows how global partnerships can still make a meaningful difference in crisis situations.
Have An Advert Or Article You Want Us To Publish? Email: swiftnewsug@gmail.com
